Clearside Biomedical Announces Publication of Consensus Guidelines for Drug Delivery Via Suprachoroidal Space Injection In Peer-Reviewed Industry Journal, RETINA

5/21/24 7:13:23 AM ET

$CLSD

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $CLSD alert in real time by email

Expert Panel of Ophthalmologists Developed Professional Guidelines in Using the Innovative Technique for Retinal Therapeutic Delivery.
Current Clinical Evidence and Physician Experience Support SCS Injection as a Safe and Effective Method for Delivering Retinal and Choroidal Therapeutics

Get the next $CLSD alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CLSD

Date	Price Target	Rating	Analyst
8/21/2024	$6.00	Buy	Chardan Capital Markets
6/25/2024	$5.00	Outperform	Oppenheimer
3/11/2022	$11.00 → $10.00	Market Outperform	JMP Securities
12/15/2021	$19.00 → $9.00	Outperform	Wedbush
7/29/2021	$10.00	Buy	HC Wainwright & Co.

More analyst ratings

$CLSD
Press Releases

Fastest customizable press release news feed in the world

Clearside Biomedical Announces Third Quarter 2024 Financial Results and Provides Corporate Update
- Recent ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieved All Primary and Secondary Outcomes - - Positive Topline Results Support Advancing CLS-AX to Phase 3 Targeting a Differentiated Flexible Dosing Approach Similar to a Biologic with the Potential Extended Duration of a Tyrosine Kinase Inhibitor (TKI) - - Recent Commercial Licensing Agreement for China by a Global Ophthalmic Pharmaceutical Company Provides Strategic Validation of Clearside's Suprachoroidal Platform - - Compelling Data Presentations at AAO Demonstrated Potential Safety and Efficacy Benefits of Suprachoroidal Delivery Using Clearside's Proprietary SCS Microinjector® in Multiple Clinical Programs - - M
11/12/24 4:05:00 PM ET
$CLSD
Biotechnology: Pharmaceutical Preparations
Health Care
Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema
- Partnership Creates New Opportunities to Address Unmet Needs Related to Posterior Segment Eye Diseases in China - - Agreement Provides Additional Validation for Clearside's Suprachoroidal Space (SCS®) Delivery Platform - ALPHARETTA, Ga., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that the Company's Asia-Pacific partner, Arctic Vision, has signed a new commercial collaboration agreement with Santen Pharmaceutical Co., Ltd. for ARVN001, branded in the U.S. as XIPERE®, for the treatment of uveitic mac
11/7/24 9:05:00 AM ET
$CLSD
Biotechnology: Pharmaceutical Preparations
Health Care
Clearside Biomedical to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference
ALPHARETTA, Ga., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today George Lasezkay, PharmD, JD, President and Chief Executive Officer, and Victor Chong, M.D., MBA, Chief Medical Officer and EVP, Head of Research & Development, will participate in a fireside chat at the Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024 at 8:00 a.m. ET in New York, NY. A link to the live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. An archive of
11/6/24 7:05:00 AM ET
$CLSD
Biotechnology: Pharmaceutical Preparations
Health Care

$CLSD
Leadership Updates

Live Leadership Updates

Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors
ALPHARETTA, Ga., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today the appointment of Tony Gibney as Chair of its Board of Directors, effective November 1, 2024. Mr. Gibney, who joined Clearside's Board as an independent director in April 2024, succeeds Clay Thorp, who will continue serving as a member of the Board. George Lasezkay, PharmD, JD, President and Chief Executive Officer, Clearside Biomedical, commented, "Tony is a highly respected member of our Board, bringing a wealth of strategic leadership experie
11/4/24 7:05:00 AM ET
$CLSD
Biotechnology: Pharmaceutical Preparations
Health Care
Clearside Biomedical Appoints Dr. Glenn Yiu to its Scientific Advisory Board
ALPHARETTA, Ga., July 11, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today the appointment of Glenn C. Yiu, M.D., Ph.D., Professor of Ophthalmology at the University of California, Davis, to its Scientific Advisory Board (SAB), which is comprised of industry-leading retinal physicians who provide medical and scientific expertise and input on the Company's research and development programs. "We are privileged to welcome Dr. Yiu to our SAB, given his leadership in the research and adoption of new delivery approaches for t
7/11/24 7:05:00 AM ET
$CLSD
Biotechnology: Pharmaceutical Preparations
Health Care
Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors
ALPHARETTA, Ga., April 16, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Anthony S. Gibney has been appointed to the Company's Board of Directors, effective April 15, 2024. "We are delighted to welcome Tony to our Board of Directors as we build on our leadership in delivering therapeutics to the suprachoroidal space," said Clay Thorp, Chair of the Clearside Board of Directors. "We believe Tony's significant experience driving value for biotech companies through successful pipeline development, financing, partnerin
4/16/24 7:05:00 AM ET
$CLSD
Biotechnology: Pharmaceutical Preparations
Health Care

Clearside Biomedical Announces Third Quarter 2024 Financial Results and Provides Corporate Update
- Recent ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieved All Primary and Secondary Outcomes - - Positive Topline Results Support Advancing CLS-AX to Phase 3 Targeting a Differentiated Flexible Dosing Approach Similar to a Biologic with the Potential Extended Duration of a Tyrosine Kinase Inhibitor (TKI) - - Recent Commercial Licensing Agreement for China by a Global Ophthalmic Pharmaceutical Company Provides Strategic Validation of Clearside's Suprachoroidal Platform - - Compelling Data Presentations at AAO Demonstrated Potential Safety and Efficacy Benefits of Suprachoroidal Delivery Using Clearside's Proprietary SCS Microinjector® in Multiple Clinical Programs - - M
11/12/24 4:05:00 PM ET
$CLSD
Biotechnology: Pharmaceutical Preparations
Health Care
Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024
ALPHARETTA, Ga., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its third quarter 2024 financial results will be reported on Tuesday, November 12, 2024 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. The live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. The live call can be accessed by dialing (877) 545-0523 (
10/31/24 7:05:00 AM ET
$CLSD
Biotechnology: Pharmaceutical Preparations
Health Care
Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes
- Maintained Stable Visual Acuity and Anatomical Control Over 9 Months - - Positive Safety Profile with No Ocular or Treatment-Related Serious Adverse Events - - 67% of CLS-AX Participants Did Not Require Any Additional Treatment up to 6 Months - - Reduced Treatment Burden by 84% Over 6 Months - - Webcast and Conference Call Today at 8:00 A.M. ET with Management and Key Opinion Leader and Board-Certified Retinal Specialist, Roger Goldberg, M.D., MBA - ALPHARETTA, Ga., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced
10/9/24 6:30:00 AM ET
$CLSD
Biotechnology: Pharmaceutical Preparations
Health Care

Clearside Biomedical Announces Publication of Consensus Guidelines for Drug Delivery Via Suprachoroidal Space Injection In Peer-Reviewed Industry Journal, RETINA

Chat with this insight

Recent Analyst Ratings for $CLSD

$CLSD Press Releases

Fastest customizable press release news feed in the world

Clearside Biomedical Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema

Clearside Biomedical to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference

$CLSD Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Medical Officer Chong Ngai Hang Victor bought $36,500 worth of shares (36,500 units at $1.00), increasing direct ownership by 57% to 100,000 units (SEC Form 4)

Chief Medical Officer Chong Ngai Hang Victor bought $24,910 worth of shares (23,500 units at $1.06), increasing direct ownership by 59% to 63,500 units (SEC Form 4)

Amendment: New insider Chong Ngai Hang Victor claimed ownership of 10,000 shares (SEC Form 3)

$CLSD Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Medical Officer Chong Ngai Hang Victor bought $36,500 worth of shares (36,500 units at $1.00), increasing direct ownership by 57% to 100,000 units (SEC Form 4)

Chief Medical Officer Chong Ngai Hang Victor bought $24,910 worth of shares (23,500 units at $1.06), increasing direct ownership by 59% to 63,500 units (SEC Form 4)

Yerxa Benjamin R bought $10,235 worth of shares (7,813 units at $1.31), increasing direct ownership by 77% to 17,957 units (SEC Form 4)

$CLSD Leadership Updates

Live Leadership Updates

Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors

Clearside Biomedical Appoints Dr. Glenn Yiu to its Scientific Advisory Board

Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors

$CLSD Financials

Live finance-specific insights

$CLSD Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Clearside Biomedical Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024

Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes

Chardan Capital Markets initiated coverage on Clearside Biomedical with a new price target

Oppenheimer initiated coverage on Clearside Biomedical with a new price target

JMP Securities reiterated coverage on Clearside Biomedical with a new price target

$CLSD FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for XIPERE issued to CLEARSIDE BIOMEDICAL, INC

FDA Approval for SUSVIMO issued to CLEARSIDE BIOMEDICAL, INC

$CLSD SEC Filings

SEC Form 10-Q filed by Clearside Biomedical Inc.

Clearside Biomedical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Clearside Biomedical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

$CLSD Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by Clearside Biomedical Inc. (Amendment)

SEC Form SC 13G/A filed by Clearside Biomedical Inc. (Amendment)

SEC Form SC 13G/A filed by Clearside Biomedical Inc. (Amendment)

$CLSD Market Insights

Live Market Insights

Needham Reiterates Buy on Clearside Biomedical, Maintains $4 Price Target

Why Is Clearside Biomedical Stock Gaining Today?

Clearside Biomedical shares are trading higher after Oppenheimer initiated coverage with an Outperform rating and a price target of $5.

Recent Analyst Ratings for
$CLSD

$CLSD
Press Releases

$CLSD
Insider Trading

$CLSD
Insider Purchases

$CLSD
Leadership Updates

$CLSD
Financials

$CLSD
Analyst Ratings

$CLSD
FDA approvals

$CLSD
SEC Filings

$CLSD
Large Ownership Changes

$CLSD
Market Insights